tirzepatide surpass-4 SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Lilly's tirzepatide achieves all primary
Pay in 4 interest-free payments of $6.00 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Live Spec
Lilly's tirzepatide achieves all primary and key secondary study outcomes against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk in SURPASS 4 trial Eli Lilly and Company Tirzepatide for diabetes: on track to SURPASS current therapy Nature Medicine Post Hoc Analysis of SURPASS 1 to 5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics Diabetes Therapy Springer Nature Link The Association Between Tirzepatide Versus Insulin Glargine and NT proBNP Levels in People With Type 2 Diabetes With or at Elevated Risk for Cardiovascular Disease: Post hoc Analyses of SURPASS 4 Circulation A Narrative Review on Clinical Evidence of Tirzepatide's Role in Addressing Type 2 Diabetes and Obesity Management Rathakrishnan Clinical Diabetology Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS 5 Randomized Clinical Trial PMC
Store: www.allread.ai · Domain: www.allread.ai



























